Ballicules.com

Netarsudil

RHOPRESSA

What it isRho kinase inhibitor increasing trabecular outflow; open-angle glaucoma and ocular hypertension.

Why this oneIt acts at the trabecular meshwork, the actual site of outflow resistance, and can add to any other glaucoma-drop class.

What limits itConjunctival hyperemia, corneal verticillata, and small conjunctival hemorrhages commonly limit acceptance.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Elevated IOP in open-angle glaucoma or ocular hypertensionadult1 drop affected eye(s) QHS1 drop affected eye(s) QHS1 drop QD (evening)

Renal Undefined

Hepatic Undefined

If a dose is missed, resume with the next evening dose

Instructions

Cautions

Adverse reactions

Pregnancy No human data; systemic exposure low; IV animal studies showed embryofetal harm at high exposures

Lactation No data; low systemic exposure after topical ocular use

NO BOXED WARNINGS

Principal riskConjunctival hyperemia and corneal verticillata

Cost, est. cash$200–$1,000/month

Generic entry2034 est.

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryNot assigned — PLLR-era drug

Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Mechanism of action: Netarsudil ballicule

Netarsudil ballicule: receptor binding, kinetics and half-life diagram

Open Netarsudil in the interactive console ↗

Memory aids: mascots and interaction avatars

Netarsudil RHOPRESSA mascot mnemonic cartoon
“Netter Sue’s Row pressure”

Open Netarsudil in the interactive console ↗